|
1
|
Alewine C, Hassan R and Pastan I: Advances
in anticancer immunotoxin therapy. Oncologist. 20:176–185. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akbari B, Farajnia S, Ahdi Khosroshahi S,
Safari F, Yousefi M, Dariushnejad H and Rahbarnia L: Immunotoxins
in cancer therapy: Review and update. Int Rev Immunol. 36:207–219.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kreitman RJ, Dearden C, Zinzani PL,
Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich
S, Gotic M, et al: Moxetumomab pasudotox in relapsed/refractory
hairy cell leukemia. Leukemia. 32:1768–1777. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin-Killias P, Stefan N, Rothschild S,
Plückthun A and Zangemeister-Wittke U: A novel fusion toxin derived
from an EpCAM-specific designed ankyrin repeat protein has potent
antitumor activity. Clin Cancer Res. 17:100–110. 2011. View Article : Google Scholar
|
|
5
|
Prince HM, Duvic M, Martin A, Sterry W,
Assaf C, Sun Y, Straus D, Acosta M and Negro-Vilar A: Phase III
placebo-controlled trial of denileukin diftitox for patients with
cutaneous T-cell lymphoma. J Clin Oncol. 28:1870–1877. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Onda M, Nagata S, FitzGerald DJ, Beers R,
Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, et
al: Characterization of the B cell epitopes associated with a
truncated form of Pseudomonas exotoxin (PE38) used to make
immunotoxins for the treatment of cancer patients. J Immunol.
177:8822–8834. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu W, Onda M, Lee B, Kreitman RJ, Hassan
R, Xiang L and Pastan I: Recombinant immunotoxin engineered for low
immunogenicity and antigenicity by identifying and silencing human
B-cell epitopes. Proc Natl Acad Sci USA. 109:11782–11787. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Onda M, Beers R, Xiang L, Lee B, Weldon
JE, Kreitman RJ and Pastan I: Recombinant immunotoxin against
B-cell malignancies with no immunogenicity in mice by removal of
B-cell epitopes. Proc Natl Acad Sci USA. 108:5742–5747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mazor R, Vassall AN, Eberle JA, Beers R,
Weldon JE, Venzon DJ, Tsang KY, Benhar I and Pastan I:
Identification and elimination of an immunodominant T-cell epitope
in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc
Natl Acad Sci USA. 109:E3597–E3603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Onda M, Beers R, Xiang L, Nagata S, Wang
Q-C and Pastan I: An immunotoxin with greatly reduced
immunogenicity by identification and removal of B cell epitopes.
Proc Natl Acad Sci USA. 105:11311–11316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu H, Seijsing J, Frejd FY, Tolmachev V
and Gräslund T: Target-specific cytotoxic effects on
HER2-expressing cells by the tripartite fusion toxin
ZHER2:2891-ABD-PE38X8, including a targeting affibody
molecule and a half-life extension domain. Int J Oncol. 47:601–609.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Altai M, Liu H, Orlova A, Tolmachev V and
Gräslund T: Influence of molecular design on biodistribution and
targeting properties of an Affibody-fused HER2-recognising
anticancer toxin. Int J Oncol. 49:1185–1194. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Weldon JE, Skarzynski M, Therres JA,
Ostovitz JR, Zhou H, Kreitman RJ and Pastan I: Designing the
furin-cleavable linker in recombinant immunotoxins based on
Pseudomonas exotoxin A. Bioconjug Chem. 26:1120–1128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mazor R, Onda M, Park D, Addissie S, Xiang
L, Zhang J, Hassan R and Pastan I: Dual B- and T-cell
de-immunization of recombinant immunotoxin targeting mesothelin
with high cytotoxic activity. Oncotarget. 7:29916–29926. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wurch T, Pierré A and Depil S: Novel
protein scaffolds as emerging therapeutic proteins: From discovery
to clinical proof-of-concept. Trends Biotechnol. 30:575–582. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zielinski R, Lyakhov I, Jacobs A, Chertov
O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R
and Capala J: Affitoxin - a novel recombinant, HER2-specific,
anticancer agent for targeted therapy of HER2-positive tumors. J
Immunother. 32:817–825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zielinski R, Lyakhov I, Hassan M, Kuban M,
Shafer-Weaver K, Gandjbakhche A and Capala J: HER2-affitoxin: A
potent therapeutic agent for the treatment of HER2-overexpressing
tumors. Clin Cancer Res. 17:5071–5081. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Simon M, Stefan N, Borsig L, Plückthun A
and Zangemeister-Wittke U: Increasing the antitumor effect of an
EpCAM-targeting fusion toxin by facile click PEGylation. Mol Cancer
Ther. 13:375–385. 2014. View Article : Google Scholar
|
|
19
|
Ham S, Min KA, Yang JW and Shin MC: Fusion
of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R)
affibody for enhanced brain cancer therapy. Arch Pharm Res.
40:1094–1104. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nilvebrant J and Hober S: The
albumin-binding domain as a scaffold for protein engineering.
Comput Struct Biotechnol J. 6:e2013030092013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alm T, Yderland L, Nilvebrant J, Halldin A
and Hober S: A small bispecific protein selected for orthogonal
affinity purification. Biotechnol J. 5:605–617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nilvebrant J, Åstrand M, Löfblom J and
Hober S: Development and characterization of small bispecific
albumin-binding domains with high affinity for ErbB3. Cell Mol Life
Sci. 70:3973–3985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nilvebrant J, Åstrand M, Georgieva-Kotseva
M, Björnmalm M, Löfblom J and Hober S: Engineering of bispecific
affinity proteins with high affinity for ERBB2 and adaptable
binding to albumin. PLoS One. 9:e1030942014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hynes NE and MacDonald G: ErbB receptors
and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tai W, Mahato R and Cheng K: The role of
HER2 in cancer therapy and targeted drug delivery. J Control
Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
von Minckwitz G, Procter M, de Azambuja E,
Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N,
Clark E, et al: APHINITY Steering Committee and Investigators:
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast
cancer. N Engl J Med. 377:122–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Verma S, Miles D, Gianni L, Krop IE,
Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, et al
EMILIA Study Group: Trastuzumab emtansine for HER2-positive
advanced breast cancer. N Engl J Med. 367:1783–1791. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lindbo S, Garousi J, Åstrand M, Honarvar
H, Orlova A, Hober S and Tolmachev V: Influence of
histidine-containing tags on the biodistribution of ADAPT scaffold
proteins. Bioconjug Chem. 27:716–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garousi J, Lindbo S, Nilvebrant J, Åstrand
M, Buijs J, Sandström M, Honarvar H, Orlova A, Tolmachev V and
Hober S: ADAPT, a novel scaffold protein-based probe for
radionuclide imaging of molecular targets that are expressed in
disseminated cancers. Cancer Res. 75:4364–4371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hopp J, Hornig N, Zettlitz KA, Schwarz A,
Fuss N, Müller D and Kontermann RE: The effects of affinity and
valency of an albumin-binding domain (ABD) on the half-life of a
single-chain diabody-ABD fusion protein. Protein Eng Des Sel.
23:827–834. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Makrides SC, Nygren PÅ, Andrews B, Ford
PJ, Evans KS, Hayman EG, Adari H, Uhlén M and Toth CA: Extended in
vivo half-life of human soluble complement receptor type 1 fused to
a serum albumin-binding receptor. J Pharmacol Exp Ther.
277:534–542. 1996.PubMed/NCBI
|
|
33
|
Orlova A, Jonsson A, Rosik D, Lundqvist H,
Lindborg M, Abrahmsen L, Ekblad C, Frejd FY and Tolmachev V:
Site-specific radiometal labeling and improved biodistribution
using ABY-027, a novel HER2-targeting affibody
molecule-albumin-binding domain fusion protein. J Nucl Med.
54:961–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jonsson A, Dogan J, Herne N, Abrahmsén L
and Nygren PÅ: Engineering of a femtomolar affinity binding protein
to human serum albumin. Protein Eng Des Sel. 21:515–527. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gunneriusson E, Nord K, Uhlén M and Nygren
P: Affinity maturation of a Taq DNA polymerase specific affibody by
helix shuffling. Protein Eng. 12:873–878. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garousi J, Lindbo S, Honarvar H, Velletta
J, Mitran B, Altai M, Orlova A, Tolmachev V and Hober S: Influence
of the N-terminal composition on targeting properties of
radiometal-labeled anti-HER2 scaffold protein ADAPT6.
Bioconjug Chem. 27:2678–2688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pastan I, Beers R and Bera TK: Recombinant
immunotoxins in the treatment of cancer. Methods Mol Biol.
248:503–518. 2004.PubMed/NCBI
|
|
38
|
Zahnd C, Kawe M, Stumpp MT, de Pasquale C,
Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK,
Waibel R, et al: Efficient tumor targeting with high-affinity
designed ankyrin repeat proteins: Effects of affinity and molecular
size. Cancer Res. 70:1595–1605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thurber GM, Schmidt MM and Wittrup KD:
Antibody tumor penetration: Transport opposed by systemic and
antigen-mediated clearance. Adv Drug Deliv Rev. 60:1421–1434. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Heldin CH, Rubin K, Pietras K and Östman
A: High interstitial fluid pressure - an obstacle in cancer
therapy. Nat Rev Cancer. 4:806–813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Roopenian DC and Akilesh S: FcRn: The
neonatal Fc receptor comes of age. Nat Rev Immunol. 7:715–725.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schmidt MM and Wittrup KD: A modeling
analysis of the effects of molecular size and binding affinity on
tumor targeting. Mol Cancer Ther. 8:2861–2871. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nielsen R, Christensen EI and Birn H:
Megalin and cubilin in proximal tubule protein reabsorption: From
experimental models to human disease. Kidney Int. 89:58–67. 2016.
View Article : Google Scholar : PubMed/NCBI
|
